Does persistently low 25-hydroxyvitamin D despite high-dose oral supplementation indicate malabsorption or increased catabolism?

When serum 25-hydroxyvitamin D [25(OH)D] levels remain low despite high-dose supplementation—typically defined as doses exceeding 4,000 to 10,000 IU/day—it serves as a clinical indicator that the issue lies in physiological processing rather than insufficient intake.

Clinical evidence of non-response

In healthy individuals, high-dose supplementation reliably increases serum 25(OH)D. However, approximately 10–15% of the population may be "non-responders."

• Celiac disease and IBD: Patients with celiac disease often show a blunt or nonexistent response to oral D3 until a gluten-free diet is initiated, as villous atrophy directly inhibits the absorption of fat-soluble vitamins.
• Dose-response failure: Studies indicate that if serum levels fail to rise after 8–12 weeks of doses as high as 50,000 IU weekly, the likelihood of underlying malabsorption or accelerated clearance is high. In these cases, clinicians often transition to calcifediol (pre-hydroxylated vitamin D) or parenteral administration to bypass the gut.

Mechanistic explanations

The failure to maintain adequate 25(OH)D levels is driven by two primary physiological bottlenecks:

• Impaired Intestinal Absorption: Vitamin D is a fat-soluble nutrient that requires bile salts for micelle formation and pancreatic lipase for solubilization. Conditions like Small Intestinal Bacterial Overgrowth (SIBO), exocrine pancreatic insufficiency, or inflammatory bowel disease (IBD) disrupt the chylomicron-mediated transport required for vitamin D to reach the liver.
• Increased Catabolism: The enzyme CYP24A1 is the primary driver of vitamin D clearance, converting 25(OH)D into the inactive metabolite 24,25(OH)2D3. High levels of FGF23 or 1,25-dihydroxyvitamin D3 can upregulate this enzyme through a feedback loop, accelerating the breakdown of the vitamin before it can provide systemic benefit. Additionally, certain medications (e.g., phenytoin) upregulate CYP3A4, further increasing catabolic rates.

Bottom line

Persistently low vitamin D despite high-dose oral intake is a validated clinical marker for intestinal malabsorption (such as Celiac or SIBO) or accelerated metabolic catabolism via the CYP24A1 pathway, rather than simple dietary deficiency.